For subscribers
US approval of Alzheimer's drug offers hope to patients in S'pore too
Sign up now: Get ST's newsletters delivered to your inbox
Biogen said on Tuesday it expects to begin shipping its newly approved Alzheimer's drug Aduhelm in about two weeks.
United States regulators have for the first time approved a drug that can slow the progression of Alzheimer's disease, the most common type of dementia, offering hope for the growing pool of such patients here as well.
Current medications are able to treat just the symptoms of Alzheimer's, a disease which robs patients of their memory and cognitive abilities as the cells in their brains that process, store and retrieve information degenerate and die.
